Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the